S

Sanofi

Global pharma company; vaccines and R&D

Technologist

Full-TimePosted on 10/21/2026Deadline 10/28/26
$49.34/hr
Mid
Bachelor's, Master's
Toronto, ON, Canada
In Person
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • A four-year Bachelor's degree in Chemistry, Biochemistry, Immunology, Biomedical Sciences, or Molecular Biology, plus at least two years of relevant work experience; alternatively, a four-year Bachelor's degree and a two-year Master's degree in one of those fields, plus at least eighteen months of relevant experience.
  • Standard analytical laboratory techniques, including accurate transfer of weighed material and accurate volumetric measurement.
  • Sound knowledge and practical expertise in immunochemical assays.
  • Sound knowledge and practical expertise in chemical and biochemical assays.
  • Theoretical and research-related knowledge in Chemistry, Biochemistry, Immunology, and Cell Biology.
  • Sound knowledge of Good Manufacturing Practice requirements, including Good Documentation Practices.
  • Computer knowledge covering hardware, software, and interfaces, including Microsoft Office, LIMS, SAP, and FMS/BMS.
  • Technical writing skills.
Responsibilities
  • Coordinate and perform assigned routine immunochemical and instrumental assays in accordance with existing SOPs, including ELISAs, cell-based assays, SDS-PAGE and densitometry, identity testing by Western Blot, Dot Blot, LC-MS, or FTIR, and HPLC, IC, GC, UV-VIS, TOC, and osmometry.
  • Perform daily maintenance and system-suitability checks for test-related equipment; ensure cleaning procedures, calibration, or validation meet testing requirements, and alert others to issues.
  • Coordinate and perform routine in-house wet-chemistry tests on in-process materials or final products, including micro-Kjeldahl nitrogen determination, aluminum determination by complexometric titration, and identity testing by TLC.
  • Perform wet-chemistry and identity testing on raw materials according to in-house SOPs and Pharmacopoeias.
  • Assist with troubleshooting invalid or unexpected results.
  • Qualify critical reagents according to SOPs, as required.
  • Maintain test reagents, inventory, and supply, replenishing reagents in a timely manner to avoid testing delays.
  • Complete and verify test-related documents accurately and on time, including LIMS data, worksheets, log books, test requisitions, calculation and data-entry checks, transcription checks, and electronic-data and audit-trail reviews, as applicable.
  • Manage samples outsourced to approved contract laboratories, including preparing test request and shipping forms, reviewing laboratory certificates and test results, and transcribing results into LIMS or internal QC release documents, as required.
  • Follow applicable divisional, departmental, and test SOPs, protocols, and procedures; review SOPs annually and document training.
  • Keep personal training and qualification current according to the qualification plan, with no overdue training.
  • Identify and notify the manager of laboratory non-conformances; initiate LIRs and contribute to laboratory investigations and deviation reports, provide documentation support to expedite closures, and participate in root-cause analysis to identify corrective actions for CAPA and events.
  • Maintain the work area, including cleaning benches and work surfaces, maintaining equipment, and disposing of biohazardous and chemical waste.
  • Complete assigned laboratory duties in a timely manner.
  • Maintain general laboratory equipment, including balances, refrigerators, freezers, and water purification systems; perform routine calibration checks, cleaning, and preventative maintenance, and ensure equipment operates satisfactorily.
  • Participate in projects for existing and new products, including collaborative studies with regulatory agencies and organizations on method comparison, assay/specification harmonization, new assay development, and stability studies; attend team meetings and provide technical expertise on respective assays as required.
  • Write protocols and reports for test transfer and method validation as required.
  • Execute studies under approved protocols for test transfer, new method validations, and existing method revalidation.
  • Complete on-the-job training according to current lesson plans and document it as required.
  • Participate in regularly scheduled GMP updates and safety training.
  • Complete required tests and training on site procedures, USP, EP, ACS, and related materials as required.
  • Assist in training new staff or existing personnel as required.
  • Attend and participate in relevant training sessions, including discussion and presentation.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Associated Press
Oct 19th, 2026
Enable Injections wins first Japan approval for enFuse on-body injector via Sanofi's CirCLIQ

Enable Injections has won its first commercial product approval in Japan. The country's Ministry of Health, Labour and Welfare approved the company's enFuse On-Body Delivery System through Sanofi's CirCLIQ Injector. The device delivers a subcutaneous form of Sarclisa (isatuximab) with the push of a button, for treating multiple myeloma. It is the first anticancer treatment given through an on-body injector in Japan. The approval follows recent clearances in the US and Europe. Japan approved Sarclisa SC in June 2026, backed by the IRAKLIA phase 3 study, which showed the subcutaneous form was non-inferior to intravenous delivery. "We're proud to partner with Sanofi to bring our enFuse technology to patients in Japan," said Michael D. Hooven, chairman and chief executive officer of Enable.

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...